MET and non-small cell lung carcinoma: A non-small cell lung cancer (NSCLC) harboring a MET exon 14 skipping mutation upon treatment with crizotinib, a MET/ALK/ROS1 inhibitor, was initially reported in 2015 (Jenkins et al., 2015; Paik et al., 2015).